Researchers at Children’s Hospital of Philadelphia (CHOP) have made significant progress in understanding how genetic factors contribute to blood disorders in individuals with Down syndrome. The study, led by Kaoru Takasaki, MD, focuses on the interaction between an extra copy of chromosome 21 (trisomy 21) and mutations in the GATA1 gene. These interactions are linked to conditions such as transient abnormal myelopoiesis (TAM) and myeloid leukemia associated with Down syndrome (ML-DS).
The research was published in Stem Cell Reports and explores how these genetic abnormalities influence cell behavior. It is known that patients with Down syndrome often experience abnormal blood cell patterns early in life, including high red blood cell counts at birth and low platelet levels.
The study used advanced stem cell techniques to engineer human stem cells into four groups: one with only the extra chromosome 21, one with only the GATA1 mutation, one with both, and a control group with neither. Researchers analyzed thousands of individual blood-forming cells to determine which genes were active in each scenario.
Findings revealed that each genetic factor altered blood development differently. The GATA1 mutation affected red blood cell production and increased white blood cells, while the extra chromosome 21 boosted red blood cell production but negatively impacted platelet production. When both factors were present, their effects became more complex, leading to an environment conducive to leukemia development.
“Our findings help paint a picture of how two genetic alterations in Down syndrome interact to set the stage for blood cancers,” said Kaoru Takasaki, MD. “We hope these insights will catalyze further research aimed at improving screening protocols and advancing targeted treatment for at-risk children.”
This research received support from several organizations including NIH grants R01 HL151260 and R01 DK090969.
